The procurement of reagents for single cell DNA sequencing.


The HIV and AIDS Malignancy Branch, in the National Cancer Institute, National Institutes of Health, Dept. of Health and Human Services requires the purchase of a reagents for single cell DNA sequencing. We have an ongoing project to study cell types and DNA mutations in diseased clinical samples obtained from patients enrolled in clinical trials the NIH. We need to process clinical samples using this new technology for this translational project.


This is a Firm Fixed-Price Purchase Order.



To be compatible with existing instrumentation (single cell DNA sequencing), the following product features/characteristics listed below are required.

  The platform must:

  • utilize droplet microfluidic technology to rapidly encapsulate, process, and profile 5,000 to 10,000 individual cells for multi-analyte detection including single-cell DNA and Protein analysis.
  • utilize a unique two-step workflow, including (1) cell encapsulation and protease incubation to lyse cells and allow access to DNA within individual droplets and (2) barcode addition and reagent introduction for target identification and amplification.
  • allow for target amplification without use of whole genome amplification methods (e.g. multiple displacement amplification).
  • have the capability to do both cell encapsulation and barcode/reagent addition on the same cartridge.
  • take no more than 4 hours of hands-on time from cell suspension to sequencing-ready libraries.
  • be compatible with an Illumina sequencing platforms MiSeq System, Illumina HiSeq 2500 System, Illumina Novaseq System.
  • allow for robust DNA detection of single-nucleotide variants (SNVs), small insertion/deletions (indels), and copy number aberrations across regions targeted by gene specific primers.
  • capable of operating in a mode to perform targeted DNA detection and detect protein analytes from the same cell.
  • capable of detecting subclones present in at least 1% of the population.


The items shall be delivered within 8 weeks of the purchase order award.

Delivery will be to the following address:

National Institutes of Health

Bethesda, MD 20892


The Contractor shall warrant that any instruments, equipment, components, or other supplies (“Supplies”) procured by this purchase are free of defects in design, material, or manufacture for a period of at least one (1) calendar year from date of acceptance by the Government.

The Contractor shall warrant that all consumables or expendable parts are free of defects in design, material or manufacture for a period of at least 90 calendar days from date of acceptance by the Government.

Supplies which are repaired or replaced shall be warranted for the remainder of the initial warranty period or for 90-days – whichever is greater.


Due to the current COVID-19 pandemic, please pay close attention to the following delivery instructions and ensure that sufficient information is included in the quote to be considered for an award. Please be aware that due to the fluidity of the existing pandemic, instructions may be updated as needed after award.

  • All quotes must include confirmation that equipment is or will be available for delivery by the due date
  • Quoters must confirm:
    • Willingness to store or hold equipment until NCI is ready to accept the equipment at no additional cost.
    • The equipment will not be sold to another company in the event NCI is not ready to accept delivery due to unanticipated changes related to COVID-19.
    • Training as identified in Section 4 may be made available and provided to required staff at different times and dates at no additional cost.
  • Communicate and follow instructions from the Technical Point of Contact (TPOC) to coordinate delivery, installation, and training. The delivery address and TPOC’s information will be provided at time of award and must be included as part of the order/shipping label.